Vancouver, British Columbia, April 27, 2007 – ProtoxTM Therapeutics Inc. (TSX-V:PRX) today released year-end financial statements for the 12 months ending December 31, 2006. “2006 was a transformative year for Protox,” said Dr. Fahar Merchant, President and Chief Executive Officer. “Over the course of 12 months we have made the transition from pre-clinical promise to encouraging interim clinical results with our flagship drug candidate, PRX302 in prostate cancer. Today we have two therapeutic platforms comprising multiple indications and clinical data for over 100 patients. These accomplishments will create enduring value for the company and set the stage for continued progress over the coming year.”
